File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women

TitleImpact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women
Authors
KeywordsAdherence
Bone marker
Compliance
Feedback
Ibandronate
Osteoporosis
Issue Date2009
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd
Citation
International Journal Of Rheumatic Diseases, 2009, v. 12 n. 3, p. 216-224 How to Cite?
AbstractAim: his study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis. Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (≤ 85 years old) who were naïve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed. Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients. Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction. © 2009 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/124912
ISSN
2015 Impact Factor: 1.914
2015 SCImago Journal Rankings: 0.536
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorRachman, IAen_HK
dc.contributor.authorAdam, JMFen_HK
dc.contributor.authorRoeshadi, Den_HK
dc.contributor.authorTorralba, Ten_HK
dc.contributor.authorNavarra, Sen_HK
dc.contributor.authorGamilla, Zen_HK
dc.contributor.authorCañete, Aen_HK
dc.contributor.authorde la Rosa, Men_HK
dc.contributor.authorTsai, KSen_HK
dc.contributor.authorLin, HYen_HK
dc.contributor.authorSoong, YKen_HK
dc.contributor.authorLan, JLen_HK
dc.contributor.authorHsu, HCen_HK
dc.contributor.authorTu, STen_HK
dc.contributor.authorLin, RMen_HK
dc.contributor.authorYuktanandana, Pen_HK
dc.contributor.authorSongpatanasilp, Ten_HK
dc.contributor.authorNgarmukos, Sen_HK
dc.contributor.authorSoontrapa, Sen_HK
dc.contributor.authorSoontrapa, Sen_HK
dc.contributor.authorRojanasthien, Sen_HK
dc.contributor.authorLuevitoonvechkij, Sen_HK
dc.contributor.authorLeerapan, Ten_HK
dc.contributor.authorAlbert, Aen_HK
dc.contributor.authorVanbelle, Sen_HK
dc.date.accessioned2010-10-31T11:01:07Z-
dc.date.available2010-10-31T11:01:07Z-
dc.date.issued2009en_HK
dc.identifier.citationInternational Journal Of Rheumatic Diseases, 2009, v. 12 n. 3, p. 216-224en_HK
dc.identifier.issn1756-1841en_HK
dc.identifier.urihttp://hdl.handle.net/10722/124912-
dc.description.abstractAim: his study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis. Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (≤ 85 years old) who were naïve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed. Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients. Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction. © 2009 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.en_HK
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrden_HK
dc.relation.ispartofInternational Journal of Rheumatic Diseasesen_HK
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectAdherenceen_HK
dc.subjectBone markeren_HK
dc.subjectComplianceen_HK
dc.subjectFeedbacken_HK
dc.subjectIbandronateen_HK
dc.subjectOsteoporosisen_HK
dc.subject.meshBiological Markers - blood-
dc.subject.meshBone Density Conservation Agents - administration and dosage - adverse effects-
dc.subject.meshDiphosphonates - administration and dosage - adverse effects-
dc.subject.meshOsteoporosis, Postmenopausal - metabolism - prevention and control-
dc.subject.meshBone and Bones/drug effects/metabolism-
dc.titleImpact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal womenen_HK
dc.typeArticleen_HK
dc.identifier.emailKung, AWC:awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1756-185X.2009.01413.xen_HK
dc.identifier.pmid20374349-
dc.identifier.scopuseid_2-s2.0-69149106711en_HK
dc.identifier.hkuros175027en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-69149106711&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume12en_HK
dc.identifier.issue3en_HK
dc.identifier.spage216en_HK
dc.identifier.epage224en_HK
dc.identifier.isiWOS:000269923800006-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridKung, AWC=7102322339en_HK
dc.identifier.scopusauthoridRachman, IA=12787433800en_HK
dc.identifier.scopusauthoridAdam, JMF=36167975000en_HK
dc.identifier.scopusauthoridRoeshadi, D=6504660597en_HK
dc.identifier.scopusauthoridTorralba, T=6602685307en_HK
dc.identifier.scopusauthoridNavarra, S=9269840700en_HK
dc.identifier.scopusauthoridGamilla, Z=36168318000en_HK
dc.identifier.scopusauthoridCañete, A=36168073300en_HK
dc.identifier.scopusauthoridde la Rosa, M=7101829102en_HK
dc.identifier.scopusauthoridTsai, KS=7201566015en_HK
dc.identifier.scopusauthoridLin, HY=7405572432en_HK
dc.identifier.scopusauthoridSoong, YK=24482122800en_HK
dc.identifier.scopusauthoridLan, JL=7102691190en_HK
dc.identifier.scopusauthoridHsu, HC=7402359942en_HK
dc.identifier.scopusauthoridTu, ST=7202726571en_HK
dc.identifier.scopusauthoridLin, RM=7402888405en_HK
dc.identifier.scopusauthoridYuktanandana, P=6506766406en_HK
dc.identifier.scopusauthoridSongpatanasilp, T=6504577159en_HK
dc.identifier.scopusauthoridNgarmukos, S=8701407200en_HK
dc.identifier.scopusauthoridSoontrapa, S=6701392129en_HK
dc.identifier.scopusauthoridSoontrapa, S=6701392128en_HK
dc.identifier.scopusauthoridRojanasthien, S=14519720300en_HK
dc.identifier.scopusauthoridLuevitoonvechkij, S=14519520800en_HK
dc.identifier.scopusauthoridLeerapan, T=36168491800en_HK
dc.identifier.scopusauthoridAlbert, A=7202794939en_HK
dc.identifier.scopusauthoridVanbelle, S=16235616700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats